We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
- Authors
Mallardo, Domenico; Simeone, Ester; Festino, Lucia; Tuffanelli, Marilena; Vanella, Vito; Trojaniello, Claudia; Vitale, Maria Grazia; Ottaviano, Margaret; Capone, Mariaelena; Madonna, Gabriele; Sparano, Francesca; Cioli, Eleonora; Scarpato, Luigi; Palla, Marco; Di Trolio, Rossella; Meinardi, Paolo; Caracò, Corrado; Ferrara, Gerardo; Muto, Paolo; Cavalcanti, Ernesta
- Abstract
Background: Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. The aim was to investigate the prognostic significance of IL-6 serum levels before and during treatment. Methods: Serum levels of IL-6 were correlated with clinical outcomes in a retrospective study. Results: Overall, 39 patients were enrolled. High serum levels of IL-6 (> 5.6 pg/ml) were associated with poorer survival (45.1% vs 0 deaths; OS: 16.1 ± 1.5 vs 20.8 ± 0 months, 95% CI 13,046 to 19,184) and shorter PFS (10.3 ± 1.9 vs 18.9 ± 1.5 months; 95% CI 3433 to 10,133) in patients with advanced CSCC treated with cemiplimab. In addition, patients whose IL-6 level increased after treatment with cemiplimab, independently of the basal level, had a poorer response to treatment than patients whose level was reduced or stable after immunotherapy. Conclusions: Serum levels of IL-6 at baseline and changes after cemiplimab immunotherapy may have a prognostic significance in patients with advanced cutaneous squamous cell carcinoma.
- Subjects
CEMIPLIMAB; SQUAMOUS cell carcinoma; PROGNOSIS; INTERLEUKIN-6; CELL populations
- Publication
Journal of Translational Medicine, 2023, Vol 21, Issue 1, p1
- ISSN
1479-5876
- Publication type
Article
- DOI
10.1186/s12967-023-03971-5